Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versusendocrine therapy alone in patients with HR+/HER2- early breast cancer

By sjmartinez • June 6, 2023

Slamon DJ, Fasching PA, Hurvitz S, Chia S, Crown J, Martín M, Barrios CH, Bardia A, Im SA, Yardley DA, Untch M, Huang CS, Stroyakovskiy D, Xu B, Moroose RL, Loi S, Visco F, Bee-Munteanu V, Afenjar K, Fresco R, Taran T, Chakravartty A, Zarate JP, Lteif A, Hortobagyi GN. Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer. Ther Adv Med Oncol. 2023 May 29;15:17588359231178125. doi: 10.1177/17588359231178125. PMID: 37275963; PMCID: PMC10233570.

Tags: adjuvant therapy, CDK4/6 inhibitors, Hematology/Oncology, HR+/HER2– early breast cancer, NATALEE, Publications, ribociclib

Characteristics of clinical trials associated with appeal and return on investment to participants, A Review and Framework

Fernandez Turizo MJ, Velez MA, Glenn B, Cummings AL, Segarra-Vazquez B, Gorbatov S, Park SJ, Shen C, Lind-Lebuffe JP, Unger JM, Garon EB. Characteristics of[...]

IGF2BP3 redirects glycolytic flux to promote one-carbon metabolism and RNA methylation

Sharma G, Gutierrez M, Jones AE, Kapoor S, Jaiswal AK, Neeb ZT, Rios A, Dorairaj P, Thaxton ML, Lin TL, Tran TM, Kabbani LES, Ritter[...]

Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial

Fasching PA, Stroyakovskiy D, Yardley DA, Huang CS, Crown J, Bardia A, Chia S, Im SA, Martin M, Xu B, Loi S, Barrios C, Untch[...]